Literature DB >> 17322095

Admission facility is associated with outcome of basilar artery occlusion.

Robert Müller1, Thomas Pfefferkorn, Bijan Vatankhah, Thomas E Mayer, Johannes Schenkel, Martin Dichgans, Dirk Sander, Heinrich J Audebert.   

Abstract

BACKGROUND AND
PURPOSE: Basilar artery occlusion (BAO) is a stroke subtype with poor prognosis, but recanalizing therapies have been reported to be effective. We investigated whether initial admission to telemedically linked general hospitals with subsequent stroke-center transfer is related to poorer outcome than direct admission to stroke centers.
METHODS: All BAO cases of 3 stroke centers in Munich and 1 center in Regensburg between March 1, 2003 and December 31, 2004 were included, either if patients were directly admitted to stroke centers (n=23) or had initial admission to general hospitals of the telemedical network for integrative stroke care (TEMPiS) and secondary transfer to stroke centers (n=16). BAO was defined as angiographically (CTA, MRI or conventional angiography) confirmed occlusion of the basilar artery. Baseline parameters and therapeutic procedures were recorded. One-year follow-up was conducted prospectively.
RESULTS: Differences in baseline parameters were not statistically significant. Time from onset to first angiography was significantly longer in patients with secondary transfer (mean: 355+/-93 minutes versus 222+/-198 minutes; P<0.01), mainly attributable to transfer duration (mean:156+/-73 minutes). In-hospital mortality (22% versus 75%; P<0.01) and 1-year-mortality (30% versus 81%; P<0.01) were lower for patients with direct admission to stroke centers. Fifty-two percent of directly admitted patients versus 13% of patients with secondary transfer (P=0.02) were living at home after 1 year.
CONCLUSIONS: BAO patients who were admitted primarily to community hospitals had a worse prognosis. Patients with typical symptoms should have direct access to stroke centers, or may need bridging therapies.

Entities:  

Mesh:

Year:  2007        PMID: 17322095     DOI: 10.1161/01.STR.0000260089.17105.27

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  7 in total

Review 1.  [Management of acute basilar artery occlusion].

Authors:  G Schulte-Altedorneburg; T E Mayer
Journal:  Radiologe       Date:  2007-04       Impact factor: 0.635

2.  Brain stem diffusion-weighted imaging lesion score: a potential marker of outcome in acute basilar artery occlusion.

Authors:  T-H Cho; N Nighoghossian; F Tahon; C Némoz; M Hermier; F Salkine; L Derex; P Trouillas; J-C Froment; F Turjman
Journal:  AJNR Am J Neuroradiol       Date:  2008-09-03       Impact factor: 3.825

3.  Hyperdense basilar artery sign-a reliable sign of basilar artery occlusion.

Authors:  Lara Connell; Inga Katharina Koerte; Ruediger Paul Laubender; Dominik Morhard; Jennifer Linn; Hans Christoph Becker; Maximilian Reiser; Hartmut Brueckmann; Birgit Ertl-Wagner
Journal:  Neuroradiology       Date:  2011-05-17       Impact factor: 2.804

4.  Influence of direct admission to Comprehensive Stroke Centers on the outcome of acute stroke patients treated with intravenous thrombolysis.

Authors:  Natalia Pérez de la Ossa; Mónica Millán; Juan F Arenillas; Josep Sánchez-Ojanguren; Ernest Palomeras; Laura Dorado; Cristina Guerrero; Antoni Dávalos
Journal:  J Neurol       Date:  2009-04-08       Impact factor: 4.849

Review 5.  A comprehensive review of prehospital and in-hospital delay times in acute stroke care.

Authors:  K R Evenson; R E Foraker; D L Morris; W D Rosamond
Journal:  Int J Stroke       Date:  2009-06       Impact factor: 5.266

Review 6.  Stroke telemedicine.

Authors:  Bart M Demaerschalk; Madeline L Miley; Terri-Ellen J Kiernan; Bentley J Bobrow; Doren A Corday; Kay E Wellik; Maria I Aguilar; Timothy J Ingall; David W Dodick; Karina Brazdys; Tiffany C Koch; Michael P Ward; Phillip C Richemont
Journal:  Mayo Clin Proc       Date:  2009       Impact factor: 7.616

7.  The Basilar Artery International Cooperation Study (BASICS): study protocol for a randomised controlled trial.

Authors:  Erik J R J van der Hoeven; Wouter J Schonewille; Jan Albert Vos; Ale Algra; Heinrich J Audebert; Eivind Berge; Alfonso Ciccone; Mikael Mazighi; Patrik Michel; Keith W Muir; Víctor Obach; Volker Puetz; Cristanne A C Wijman; Andrea Zini; Jaap L Kappelle
Journal:  Trials       Date:  2013-07-08       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.